Company intelligence / Profile preview

PhotoPharmics

American Fork, Utah, United Statesphotopharmics.com ↗

Ownership: Private
Development stage: Other

Overview

PhotoPharmics has developed a non-invasive, at-home phototherapy device ("Celeste") for the treatment of Parkinson’s disease. The company’s pivotal Phase 3 "Light for PD" clinical trial has surpassed key enrollment milestones with promising results reported in both motor and non-motor symptom improvement. The first subject completed the full six-month course as of September 2024. FDA submission and commercial launch are anticipated soon.

Therapeutic areas: Neurology
Modalities: Device (specialized phototherapy)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on PhotoPharmics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhotoPharmics.

Explore the full profile